ReviewFrontiers in immunology2026
Why are long-lived plasma cells long-lived?
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-Lived Plasma Cells (LLPCs) are an integral part of long-term protective humoral immunity. They can live for decades, unlike Short-Lived Plasma Cells (SLPCs), and continuously produce antibody regardless of antigen stimulation, unlike Memory B Cells (MBCs). LLPCs are critical for the sustained protective immunity against pathogens that are only intermittently present in a population but can cause significant morbidity/mortality when active-such as epidemic diseases. What drives B cell differentiation specifically to the LLPC lineage is still not fully understood; there is conflicting information on what drives the fate decisions for MBCs vs. SLPCs vs. LLPCs. Evidence suggests that although LLPC and SLPC have similar gene transcriptional profiles they differ significantly in their metabolic profiles-likely due to the demands of prolonged continuous antibody production in LLPC. These metabolic changes include increased uptake of metabolic substrates, increased mitochondrial mass/function and enhanced fuel availability via lipophagy, and enhanced proteostasis to remove misfolded proteins. However, the possibility of repeated antigen-driven generation of a large number of highly metabolically active long-lived cells is problematic for a resource-constrained organism, and it is now clear that LLPC numbers are constrained by a limited number of specialized LLPC niches in the bone marrow and other tissues. LLPCs are not intrinsically long-lived but rely on interactions with the LLPC niche to maintain their longevity. For example, activation of the CD28 receptor on LLPC by its ligands CD80/CD86 on dendritic cells (DC) in the LLPC niche results in augmented metabolism through enhanced lipophagy, intracellular long chain fatty acid availability, oxidative phosphorylation, increased mitochondrial mass and function that are necessary for LLPC survival. CD28 activation is essential for the survival of LLPC but not for SLPC, supporting the concept that enhancement of LLPC metabolic capacity by interactions with its niche plays a key role in LLPC longevity. In human health, new insights into how LLPCs survive and differentiate will impact the development of robust and long-lasting vaccinations, as well as with treatment of autoantibody-mediate autoimmune diseases and PC malignancies such as multiple myeloma (MM)-as these malignancies remain dependent on many of the same survival pathways as their nonmalignant LLPC counterparts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.